EW Stock Analysis: Buy, Sell, or Hold?
EW - Edwards Lifesciences Corp
$79.37
0.02 (0.03%)
▲
5d:
-3.24%
30d:
-8.22%
90d:
-8.62%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 22, 2026
22d
Smart Money Distribution
EW is up 4.9% this week, but smart money is buying puts. Top strike: $70 2026-05-15 with 3,743 OI. Put ratio: 76% View Scanner →
Strength: 5.0/10
Get Alerted When EW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EW trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: EW trading at deep discount. Market pricing in -4.4% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$120.46
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$74.79
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EW is currently trading at $79.36, which is considered oversold relative to its 30-day fair value range of $80.99 to $85.23. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.0) compared to its historical average (27.4). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EW is in a uptrend. The price is currently testing key support at $78.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $97.12 (+22.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EW is in a uptrend. The price is currently testing key support at $78.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $97.12 (+22.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$80.99 -
$85.23
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.4% below Wall St target ($97.12)
Fair Price Analysis
30-Day Fair Range
$80.99 -
$85.23
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$78.39
Resistance Level
$85.14
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.99
Wall Street Target
$97.12
(+22.4%)
Revenue Growth (YoY)
13.3%
Earnings Growth (YoY)
-76.6%
Profit Margin
17.7%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
24.0 vs 27.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$75.85
(-4%)
2-Year Target
$72.51
(-9%)
3-Year Target
$69.32
(-13%)
3-Yr Target (if PE normalizes)
(PE: 24→27)
$79.18
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.0, Growth: 11.7%)
$110.45
(+39%)
Base:
(SPY PE: 22.4, Growth: 11.7%)
$103.13
(+30%)
Bear:
(PE: 19.0, Growth: 11.7%)
$87.66
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 45.58 | Current EPS (TTM): $1.81
Bull Case
$165.77
(+102%)
Analyst growth 82.7%, PE expands to 50.1
Base Case
$150.70
(+84%)
Market implied 82.7%, PE stable at 45.6
Bear Case
$56.10
(-32%)
Severe decline -20.0%, PE contracts to 38.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.0 to 27.4
Stabilization Target:
$90.62
(+14.2%)
PE Expansion Potential:
+14.2%
Share & Embed Analysis
Last updated: March 30, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM
Data refreshes hourly during market hours. Next update: 2:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Scott B Ullem
SELL
13000 shares
2026-03-11
Daniel J Lippis
SELL
1019 shares
2026-03-11
Donald E Bobo Jr
SELL
11340 shares
2026-03-02
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 48 HOLD |
Advanced EW Option Strategies
Professional options setups generated by AI based on today's EW price and gamma walls.
